236 related articles for article (PubMed ID: 24357503)
1. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists.
Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B
ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503
[TBL] [Abstract][Full Text] [Related]
2. FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides.
Pang L; Kleeb S; Lemme K; Rabbani S; Scharenberg M; Zalewski A; Schädler F; Schwardt O; Ernst B
ChemMedChem; 2012 Aug; 7(8):1404-22. PubMed ID: 22644941
[TBL] [Abstract][Full Text] [Related]
3. Target Selectivity of FimH Antagonists.
Scharenberg M; Schwardt O; Rabbani S; Ernst B
J Med Chem; 2012 Nov; 55(22):9810-6. PubMed ID: 23088608
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH.
Wellens A; Lahmann M; Touaibia M; Vaucher J; Oscarson S; Roy R; Remaut H; Bouckaert J
Biochemistry; 2012 Jun; 51(24):4790-9. PubMed ID: 22657089
[TBL] [Abstract][Full Text] [Related]
5. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
[TBL] [Abstract][Full Text] [Related]
6. A flow cytometry-based assay for screening FimH antagonists.
Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B
Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870
[TBL] [Abstract][Full Text] [Related]
7. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target?
Eris D; Preston RC; Scharenberg M; Hulliger F; Abgottspon D; Pang L; Jiang X; Schwardt O; Ernst B
Chembiochem; 2016 Jun; 17(11):1012-20. PubMed ID: 26991759
[TBL] [Abstract][Full Text] [Related]
8. Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay.
Rabbani S; Jiang X; Schwardt O; Ernst B
Anal Biochem; 2010 Dec; 407(2):188-95. PubMed ID: 20705050
[TBL] [Abstract][Full Text] [Related]
9. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
Mydock-McGrane LK; Cusumano ZT; Janetka JW
Expert Opin Ther Pat; 2016; 26(2):175-97. PubMed ID: 26651364
[TBL] [Abstract][Full Text] [Related]
10. RMSD analysis of structures of the bacterial protein FimH identifies five conformations of its lectin domain.
Magala P; Klevit RE; Thomas WE; Sokurenko EV; Stenkamp RE
Proteins; 2020 Apr; 88(4):593-603. PubMed ID: 31622514
[TBL] [Abstract][Full Text] [Related]
11. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes.
Bouckaert J; Mackenzie J; de Paz JL; Chipwaza B; Choudhury D; Zavialov A; Mannerstedt K; Anderson J; Piérard D; Wyns L; Seeberger PH; Oscarson S; De Greve H; Knight SD
Mol Microbiol; 2006 Sep; 61(6):1556-68. PubMed ID: 16930149
[TBL] [Abstract][Full Text] [Related]
12. Development of an aggregation assay to screen FimH antagonists.
Abgottspon D; Rölli G; Hosch L; Steinhuber A; Jiang X; Schwardt O; Cutting B; Smiesko M; Jenal U; Ernst B; Trampuz A
J Microbiol Methods; 2010 Sep; 82(3):249-55. PubMed ID: 20620174
[TBL] [Abstract][Full Text] [Related]
13. Binding of the Bacterial Adhesin FimH to Its Natural, Multivalent High-Mannose Type Glycan Targets.
Sauer MM; Jakob RP; Luber T; Canonica F; Navarra G; Ernst B; Unverzagt C; Maier T; Glockshuber R
J Am Chem Soc; 2019 Jan; 141(2):936-944. PubMed ID: 30543411
[TBL] [Abstract][Full Text] [Related]
14. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.
Klein T; Abgottspon D; Wittwer M; Rabbani S; Herold J; Jiang X; Kleeb S; Lüthi C; Scharenberg M; Bezençon J; Gubler E; Pang L; Smiesko M; Cutting B; Schwardt O; Ernst B
J Med Chem; 2010 Dec; 53(24):8627-41. PubMed ID: 21105658
[TBL] [Abstract][Full Text] [Related]
15. Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose.
Aprikian P; Tchesnokova V; Kidd B; Yakovenko O; Yarov-Yarovoy V; Trinchina E; Vogel V; Thomas W; Sokurenko E
J Biol Chem; 2007 Aug; 282(32):23437-46. PubMed ID: 17567583
[TBL] [Abstract][Full Text] [Related]
16. Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant?
Mayer K; Eris D; Schwardt O; Sager CP; Rabbani S; Kleeb S; Ernst B
J Med Chem; 2017 Jul; 60(13):5646-5662. PubMed ID: 28471659
[TBL] [Abstract][Full Text] [Related]
17. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
Mydock-McGrane LK; Hannan TJ; Janetka JW
Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
[TBL] [Abstract][Full Text] [Related]
18. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
[TBL] [Abstract][Full Text] [Related]
19. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation.
Schwartz DJ; Kalas V; Pinkner JS; Chen SL; Spaulding CN; Dodson KW; Hultgren SJ
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15530-7. PubMed ID: 24003161
[TBL] [Abstract][Full Text] [Related]
20. Catch-bond mechanism of the bacterial adhesin FimH.
Sauer MM; Jakob RP; Eras J; Baday S; Eriş D; Navarra G; Bernèche S; Ernst B; Maier T; Glockshuber R
Nat Commun; 2016 Mar; 7():10738. PubMed ID: 26948702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
